Copenhagen-based biotechnology company developing AI-designed, de novo protein biologics—especially functional miniproteins—to target G protein-coupled receptors (GPCRs)
Copenhagen-based biotechnology company developing AI-designed, de novo protein biologics—especially functional miniproteins—to target G protein-coupled receptors (GPCRs). Its platform combines computational protein design with high-throughput screening in living human cells to create receptor agonists, antagonists, and modulators for challenging drug targets.